The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2025

Filed:

Aug. 17, 2020
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

The Brigham and Women's Hospital, Inc., Boston, MA (US);

The General Hospital Corporation, Boston, MA (US);

Inventors:

Aviv Regev, Cambridge, MA (US);

Nir Hacohen, Boston, MA (US);

Vijay K. Kuchroo, Boston, MA (US);

Ana Carrizosa Anderson, Boston, MA (US);

Orit Rozenblatt-Rosen, Cambridge, MA (US);

Jonathan Chen, Boston, MA (US);

Karin Pelka, Cambridge, MA (US);

Matan Hofree, Cambridge, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 40/11 (2025.01); A61K 40/421 (2025.01); A61K 40/4236 (2025.01); A61K 40/4242 (2025.01); G01N 33/5011 (2013.01); G01N 33/56972 (2013.01); G01N 33/57419 (2013.01); A61K 45/06 (2013.01); A61K 2239/50 (2023.05); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/47 (2013.01); G01N 2800/56 (2013.01); G01N 2800/60 (2013.01);
Abstract

The present invention is generally directed to a colorectal (CRC) cell atlas that provides methods of predicting outcomes of cancer patients and therapeutic targets for treating patients in need thereof. The atlas may be used to predict a response to immunotherapy, in particular checkpoint blockade therapy and adoptive cell transfer. Disclosed herein are previously unidentified gene programs in tumors that can be used to predict response and provide for therapeutic targets that can be used to shift a tumor to a responsive phenotype.


Find Patent Forward Citations

Loading…